Alex Azrilevich

3.0k total citations · 2 hit papers
15 papers, 2.1k citations indexed

About

Alex Azrilevich is a scholar working on Surgery, Oncology and Molecular Biology. According to data from OpenAlex, Alex Azrilevich has authored 15 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Surgery, 8 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in Alex Azrilevich's work include Bladder and Urothelial Cancer Treatments (13 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Urinary and Genital Oncology Studies (6 papers). Alex Azrilevich is often cited by papers focused on Bladder and Urothelial Cancer Treatments (13 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Urinary and Genital Oncology Studies (6 papers). Alex Azrilevich collaborates with scholars based in United States, Italy and Germany. Alex Azrilevich's co-authors include Padmanee Sharma, Arlene O. Siefker‐Radtke, Abdel Saci, Matthew D. Galsky, Andrea Necchi, Alexandre Lambert, Margitta Retz, Daniel A. Vaena, Sumanta K. Pal and Elizabeth R. Plimack and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Alex Azrilevich

15 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

2017 1.2k citations Padmanee Sharma, Margitta Retz et al. The Lancet Oncology profile →
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

2016 511 citations Padmanee Sharma, Margaret K. Callahan et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alex Azrilevich United States	8	1.6k	1.3k	443	432	347	15	2.1k
Bishoy M. Faltas United States	20	469 0.3×	730 0.5×	102 0.2×	504 1.2×	486 1.4×	74	1.5k
Nabil Adra United States	19	460 0.3×	757 0.6×	107 0.2×	622 1.4×	313 0.9×	119	1.4k
Thomas R. Nirschl United States	15	1.0k 0.6×	187 0.1×	677 1.5×	443 1.0×	222 0.6×	33	1.4k
George Philips United States	15	386 0.2×	311 0.2×	150 0.3×	254 0.6×	301 0.9×	41	916
Humberto Contreras-Trujillo United States	7	376 0.2×	257 0.2×	630 1.4×	178 0.4×	461 1.3×	9	1.2k
Catherine Mazerolles France	22	276 0.2×	635 0.5×	90 0.2×	195 0.5×	517 1.5×	59	1.4k
Koji Miyabayashi Japan	27	1.3k 0.8×	912 0.7×	232 0.5×	606 1.4×	689 2.0×	68	2.1k
Karl Heath United States	9	1.3k 0.8×	339 0.3×	490 1.1×	453 1.0×	309 0.9×	14	1.6k
Cristina Raimondi Italy	23	1.3k 0.9×	211 0.2×	152 0.3×	400 0.9×	349 1.0×	45	1.7k
Michael D. Gillett United States	8	945 0.6×	195 0.1×	556 1.3×	525 1.2×	263 0.8×	10	1.3k

Countries citing papers authored by Alex Azrilevich

Since Specialization

Citations

This map shows the geographic impact of Alex Azrilevich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alex Azrilevich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alex Azrilevich more than expected).

Fields of papers citing papers by Alex Azrilevich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alex Azrilevich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alex Azrilevich. The network helps show where Alex Azrilevich may publish in the future.

Co-authorship network of co-authors of Alex Azrilevich

This figure shows the co-authorship network connecting the top 25 collaborators of Alex Azrilevich. A scholar is included among the top collaborators of Alex Azrilevich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alex Azrilevich. Alex Azrilevich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Luke, Jason J., Josep Tabernero, Anthony M. Joshua, et al.. (2019). BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).. Journal of Clinical Oncology. 37(7_suppl). 358–358. 44 indexed citations

Moreno, Víctor, Jason J. Luke, Karen A. Gelmon, et al.. (2019). Combination of the indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i) BMS-986205 with nivolumab (nivo): Updated safety across all tumors and efficacy in advanced bladder cancer (advBC) by patient (pt) subgroup. European Urology Supplements. 18(1). e1509–e1510. 1 indexed citations

Tabernero, Josep, Karen A. Gelmon, Andréa Varga, et al.. (2019). PD47-01 BMS-986205, AN INDOLEAMINE 2,3-DIOXYGENASE 1 INHIBITOR, PLUS NIVOLUMAB: UPDATED SAFETY ACROSS ALL TUMOR COHORTS AND EFFICACY IN ADVANCED BLADDER CANCER. The Journal of Urology. 201(Supplement 4). 1 indexed citations

Wang, Li, Abdel Saci, Péter M. Szabó, et al.. (2018). EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nature Communications. 9(1). 3503–3503. 216 indexed citations

Tabernero, Josep, Jason J. Luke, Anthony M. Joshua, et al.. (2018). BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): Updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC).. Journal of Clinical Oncology. 36(15_suppl). 4512–4512. 26 indexed citations

Galsky, Matt D., Abdel Saci, Péter M. Szabó, et al.. (2018). Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator-activated receptor gamma (PPARg), and outcomes with nivolumab (nivo) in metastatic urothelial cancer (UC).. Journal of Clinical Oncology. 36(6_suppl). 511–511. 6 indexed citations

Pond, Gregory R., Guru Sonpavde, Matt D. Galsky, et al.. (2018). Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma.. Journal of Clinical Oncology. 36(6_suppl). 451–451. 1 indexed citations

Galsky, Matthew D., Abdel Saci, Péter M. Szabó, et al.. (2017). Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study. Annals of Oncology. 28. v296–v297. 49 indexed citations

Sharma, Padmanee, Margitta Retz, Arlene O. Siefker‐Radtke, et al.. (2017). Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 18(3). 312–322. 1203 indexed citations breakdown →

10.

Bajorin, Dean F., Matthew D. Galsky, Jürgen E. Gschwend, et al.. (2017). A Phase III, randomized, double-blind, multicenter study of adjuvant nivolumab vs placebo in patients (pts) with high-risk invasive urothelial carcinoma (UC; CheckMate 274). Annals of Oncology. 28. v327–v327. 6 indexed citations

11.

Galsky, Matt D., Margitta Retz, Arlene O. Siefker‐Radtke, et al.. (2016). Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: Results from the phase II CheckMate 275 study. Annals of Oncology. 27. vi567–vi567. 23 indexed citations

12.

Sharma, Padmanee, Margaret K. Callahan, Petri Bono, et al.. (2016). Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. The Lancet Oncology. 17(11). 1590–1598. 511 indexed citations breakdown →

13.

Rosenberg, Jonathan E., Petri Bono, Pavlina Spiliopoulou, et al.. (2016). Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study. Annals of Oncology. 27. vi271–vi271. 2 indexed citations

14.

Sharma, Padmanee, Petri Bono, Joseph W. Kim, et al.. (2016). Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.. Journal of Clinical Oncology. 34(15_suppl). 4501–4501. 37 indexed citations

15.

Sharma, Padmanee, Marc‐Oliver Grimm, Matthew D. Galsky, et al.. (2015). A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent. Journal for ImmunoTherapy of Cancer. 3(S2). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact